Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
Benzinga Newsdesk 1 month ago
News
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroupsNew
- New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups
- New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure
- In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients
- The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care